Literature DB >> 1871504

[Post-menopausal endometriosis developed during tamoxifen treatment].

G Le Bouëdec1, P Kauffmann, J M Pingeon, M de Latour, P Lemesle, J Dauplat.   

Abstract

The authors report a case of endometriosis (adenomyosis + endometrioma) which occurred in a female patient aged 69 years, who had undergone the menopause 15 years previously and who had been taking Tamoxifen for 7 years as an adjuvant treatment for cancer of the breast. Tamoxifen, a non-steroidal anti-estrogen derived from diethylstilbestrol, has a variable antagonist/agonist so that estrogenic stimulation of the female genital tract may occur, particularly of the endometrial mucosa. The reactivation of the endometriosic foci which had become quiescent under the impact of the natural menopause, which, by iatrogenic analogy is included in the series of paradoxical uterine effects of tamoxifen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871504

Source DB:  PubMed          Journal:  Rev Fr Gynecol Obstet        ISSN: 0035-290X


  2 in total

1.  SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial.

Authors:  Tasuku Harada; Ikuko Ohta; Yusuke Endo; Hiroshi Sunada; Hisashi Noma; Fuminori Taniguchi
Journal:  Yonago Acta Med       Date:  2018-02-05       Impact factor: 1.641

Review 2.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.